John Gandolfo, Tom Patton and Peter Cuneo to join the Board, adding significant medical technology operational, financial and turn-around experience BASKING RIDGE, N.J. , March 26, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today
Julie Bruzzone Goldstein and Tricia Wilber to join the Board, adding significant marketing, media and brand strategy experience ROCKAWAY, N.J. , March 09, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of
BASKING RIDGE, N.J. , Dec. 27, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company’s current Chairman of the Board, Carrie S. Cox , will resign from the Board effective March 31, 2020 . Ms.
Peter Staats MD, MBA, ABIPP, FIPP Joins electroCore to Lead Global Development of Company’s Non-invasive Vagus Nerve Stimulation (nVNS) Therapy Basking Ridge, NJ, June 21, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological
Comprehensive telehealth platform to facilitate the efficient procurement of gammaCore Sapphire™ CV (non-invasive vagus nerve stimulator) by known or suspected COVID-19 patients BASKING RIDGE, N.J. , Sept. 24, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage
ROCKAWAY, NJ , Oct. 07, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced the granting of the company’s motion to dismiss the federal court securities class action case filed in Trenton, NJ .
ROCKAWAY, NJ , Sept. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that on September 10, 2021 the company received Section 510(k) clearance from the United States Food and Drug Administration (FDA) of the
FDA clearance expands gammaCore label to include the acute and preventive treatment of migraine in adolescents 12 to 17 years of age ROCKAWAY, N.J. , Feb. 16, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that on
Approval makes novel non-invasive vagus nerve stimulation therapy available for prevention as well as acute treatment of migraines in adults BASKING RIDGE, N.J. , March 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced
BASKING RIDGE, N.J., July 17, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, announced today a program with UpScript, a digital healthcare platform, offering a direct-to-patient telemedicine option for gammaCore™ non-invasive vagus nerve